Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pangaea OncologyXMAD:PANG 61 EPS without NRI is €-0.10 as of Dec. 2025. GuruFocus rates XMAD:PANG with a GF Score™ of 61/100 and a GF Value™ of €2.18 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 159 Medical Diagnostics & Research companies, Pangaea Oncology ranks worse than 74.84% on this metric.
Pangaea Oncology's earnings per share without non-recurring items for the
six
months ended in Dec. 2025 was €-0.05.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.10.
During the past 3 years, the average earnings per share (NRI) Growth Rate was -6.80% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was -9.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Pangaea Oncology's EPS without NRI or its related term are showing as below:
XMAD:PANG'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -96.2 Med: -8.7 Max: 41.1
Current: -6.8
During the past 13 years, Pangaea Oncology's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 41.10% per year. The lowest was -96.20% per year. And the median was -8.70% per year.
XMAD:PANG's 3-Year EPS without NRI Growth Rate is ranked worse than 74.84% of 159
companies
in the Medical Diagnostics & Research industry
Industry Median: 10.8
vs XMAD:PANG: -6.80
Pangaea Oncology's EPS (Diluted) for the
six
months ended in Dec. 2025 was €-0.05.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.10.
Pangaea Oncology's EPS (Basic) for the
six
months ended in Dec. 2025 was €-0.05.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.10.
Pangaea Oncology (XMAD:PANG) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Pangaea Oncology EPS without NRI Related Terms
Pangaea Oncology EPS without NRI Historical Data
* Premium members only.
The historical data trend for Pangaea Oncology's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:PANG vs TMO, DHR, IDXX: EPS without NRI Comparison
For the Diagnostics & Research subindustry, Pangaea Oncology's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pangaea Oncology PE Ratio without NRI vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pangaea Oncology's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Pangaea Oncology's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.10
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pangaea Oncology (XMAD:PANG) has a EPS without NRI of €-0.10 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Pangaea Oncology and its competitors. According to the industry distribution chart, Pangaea Oncology ranks #119 out of 159 companies in the Medical Diagnostics & Research industry, placing it in the top 74.8%.
Is Pangaea Oncology's EPS without NRI too high?
Pangaea Oncology's current EPS without NRI is €-0.10. Based on the distribution chart, Pangaea Oncology ranks #119 out of 159 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Pangaea Oncology has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pangaea Oncology's EPS without NRI compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pangaea Oncology ranks #119 out of 159 companies for EPS without NRI. This places Pangaea Oncology in the lower half of its industry. The industry median EPS without NRI is 10.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Diagnostics & Research company?
The median EPS without NRI among Medical Diagnostics & Research companies is 10.80, based on 159 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Pangaea Oncology and its competitors. For the Medical Diagnostics & Research industry, the median EPS without NRI is 10.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pangaea Oncology's current EPS without NRI is €-0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pangaea Oncology stock overvalued right now?
Based on GuruFocus' analysis, Pangaea Oncology (XMAD:PANG) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.18, compared to a current price of €1.55 — trading 28.9% below its estimated fair value. The current EPS without NRI is €-0.10. Pangaea Oncology's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Pangaea Oncology (XMAD:PANG), the current EPS without NRI is €-0.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pangaea Oncology (XMAD:PANG) Overvalued in 2026?
Based on GuruFocus' analysis, Pangaea Oncology stock appears to be undervalued.
The current stock price of €1.55 is trading 28.9% below its estimated GF Value™ of €2.18.
GuruFocus considers Pangaea Oncology to be Modestly Undervalued.
Key valuation signals for XMAD:PANG:
EPS without NRI: €-0.10
GF Value™: €2.18 vs. price of €1.55 (28.9% below fair value)
No single metric tells the full story. See the XMAD:PANG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
61GF Score
Get the complete analysis for XMAD:PANG
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:PANG has been successfully added to your 
